caa a22 4500 605543003 CHVBK 20210128100924.0 cr unu---uuuuu 210128e20150601xx s 000 0 eng 10.1007/s00109-015-1251-9 doi (NATIONALLICENCE)springer-10.1007/s00109-015-1251-9 Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension [Elektronische Daten] [Kenichi Okumura, Hideyuki Kato, Osami Honjo, Siegfried Breitling, Wolfgang Kuebler, Mei Sun, Mark Friedberg] Left ventricular (LV) function influences outcomes in right ventricular (RV) failure. Carvedilol reduces mortality in LV failure and improves RV function in experimental pulmonary arterial hypertension (PAH). However, its impact on ventricular-ventricular interactions and LV function in RV afterload is unknown. We investigated effects of carvedilol on biventricular fibrosis and function in a rat model of persistent PAH. Rats were randomized into three groups: Sham controls, PAH, and PAH + carvedilol. Severe PAH was induced by 60mg/kg subcutaneous monocrotaline. In the treatment group, oral carvedilol (15mg/kg/day) was started 2weeks after monocrotaline injection and continued for 3weeks until the terminal experiment. Echocardiography and exercise performance were performed at baseline and repeated at the terminal experiment with hemodynamic measurements. LV and RV myocardium were analyzed for hypertrophy, fibrosis, and molecular signaling by protein and mRNA analysis. PAH and PAH + carvedilol rats experienced severely elevated pulmonary arterial pressures and RV hypertrophy. Despite similar RV systolic pressures, carvedilol reduced biventricular collagen content (RV fibrosis area; 13.4 ± 6.5 vs. 5.5 ± 2.7%, p < 0.001) and expression of transforming growth factor-β1 (TGFβ1) (RV TGFβ1/glyceraldehyde 3-phosphate dehydrogenase (GAPDH) ratio; 1.16 ± 0.39 vs. 0.57 ± 0.22, p < 0.01) and connective tissue growth factor (CTGF) (RV CTGF/GAPDH ratio; 0.49 ± 0.06 vs. 0.35 ± 0.17, p < 0.05). RV pro-apoptotic caspase-8 was increased in PAH compared to controls and was significantly reduced in both ventricles compared to PAH animals by carvedilol. Tissue effects were accompanied by improved biventricular systolic and diastolic performance and exercise treadmill distance (36 ± 30 vs. 80 ± 33m, p < 0.05). In RV pressure-load, carvedilol improves biventricular fibrosis and function through abrogation of TGFβ1-CTGF signaling. Key message: • RV afterload caused biventricular injury and dysfunction through TGFβ1-CTGF signaling. • Carvedilol reduced biventricular TGFβ1-CTGF signaling, fibrosis, and apoptosis. • Carvedilol improved cardiac output and biventricular function. • Improved fibrosis and hemodynamics occurred despite persistent RV afterload. Springer-Verlag Berlin Heidelberg, 2015 Pulmonary arterial hypertension nationallicence Adrenergic receptor blocker nationallicence Right heart dysfunction nationallicence Ventricular-ventricular interactions nationallicence Okumura Kenichi The Labatt Family Heart Center, Division of Cardiology and Cardiovascular Surgery, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada aut Kato Hideyuki The Labatt Family Heart Center, Division of Cardiology and Cardiovascular Surgery, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada aut Honjo Osami The Labatt Family Heart Center, Division of Cardiology and Cardiovascular Surgery, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada aut Breitling Siegfried The Keenan Research Center of the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada aut Kuebler Wolfgang The Keenan Research Center of the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada aut Sun Mei The Labatt Family Heart Center, Division of Cardiology and Cardiovascular Surgery, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada aut Friedberg Mark The Labatt Family Heart Center, Division of Cardiology and Cardiovascular Surgery, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada aut Journal of Molecular Medicine Springer Berlin Heidelberg 93/6(2015-06-01), 663-674 0946-2716 93:6<663 2015 93 109 https://doi.org/10.1007/s00109-015-1251-9 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00109-015-1251-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Okumura Kenichi The Labatt Family Heart Center, Division of Cardiology and Cardiovascular Surgery, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada aut NATIONALLICENCE 700 1- Kato Hideyuki The Labatt Family Heart Center, Division of Cardiology and Cardiovascular Surgery, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada aut NATIONALLICENCE 700 1- Honjo Osami The Labatt Family Heart Center, Division of Cardiology and Cardiovascular Surgery, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada aut NATIONALLICENCE 700 1- Breitling Siegfried The Keenan Research Center of the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada aut NATIONALLICENCE 700 1- Kuebler Wolfgang The Keenan Research Center of the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada aut NATIONALLICENCE 700 1- Sun Mei The Labatt Family Heart Center, Division of Cardiology and Cardiovascular Surgery, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada aut NATIONALLICENCE 700 1- Friedberg Mark The Labatt Family Heart Center, Division of Cardiology and Cardiovascular Surgery, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada aut NATIONALLICENCE 773 0- Journal of Molecular Medicine Springer Berlin Heidelberg 93/6(2015-06-01), 663-674 0946-2716 93:6<663 2015 93 109